Skip to content
Sign in

BIB · NASDAQ · ETF

ProShares Ultra Nasdaq Biotechnology (BIB) Price, Holdings & Fees

$361.27+1.02%+$3.65End-of-day price as of Oct 9, 2026

ProShares Ultra Nasdaq Biotechnology (BIB) closed at $361.27 on Oct 9, 2026, up 1.02% from the previous close of $357.62.

Share price, past year

1Y +11.36%

52-week range $320.23 – $367.22. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$361.27
Sep 30, 2026$353.26
Aug 31, 2026$340.33
Jul 31, 2026$324.47
Jun 30, 2026$330.78
May 29, 2026$334.30
Apr 30, 2026$359.83
Mar 31, 2026$358.53
Feb 27, 2026$355.87
Jan 30, 2026$356.90
Dec 31, 2025$343.01
Nov 28, 2025$342.85
Oct 31, 2025$335.26

Key statistics

Expense ratio
—
Net assets
$73.7M
as of May 31, 2026
Holdings
267
as of May 31, 2026
52-week range
$320.23 – $367.22

Holdings

ProShares Ultra Nasdaq Biotechnology held 267 investments worth $73.65M as of May 31, 2026. Its largest holding was N/A, at 7.35% of the fund.

ProShares Ultra Nasdaq Biotechnology largest holdings by share of net assets
#Holding% of fundValue
1N/A7.35%$5.42M
2ProShares GENIUS Money Market ETFIQMM6.80%$5.01M
3Gilead Sciences, Inc.GILD4.66%$3.43M
4Vertex Pharmaceuticals, Inc.VRTX4.65%$3.43M
5Amgen, Inc.AMGN4.48%$3.30M
6N/A3.94%$2.90M
7N/A3.26%$2.40M
8Regeneron Pharmaceuticals, Inc.REGN3.21%$2.36M
9N/A2.62%$1.93M
10Alnylam Pharmaceuticals, Inc.ALNY2.01%$1.48M
11Revolution Medicines, Inc.RVMD1.57%$1.15M
12Biogen, Inc.BIIB1.44%$1.06M
13Repurchase Agreement1.28%$944.61K
14Illumina, Inc.ILMN1.25%$921.21K
15United Therapeutics Corp.UTHR1.22%$902.05K
16Royalty Pharma plc1.20%$883.07K
17Argenx SEARGX1.19%$877.79K
18N/A1.18%$871.18K
19Insmed, Inc.INSM1.16%$851.86K
20Roivant Sciences Ltd.1.08%$793.54K
21Incyte Corp.INCY0.97%$711.91K
22Viatris, Inc.VTRS0.94%$692.11K
23Moderna, Inc.MRNA0.94%$688.97K
24Guardant Health, Inc.GH0.85%$629.00K
25INVESCO GOVT AND AGCY LEX0.81%$598.02K

Top 25 of 267 holdings, as of May 31, 2026. Percentages are of the fund's net assets.

What the fund owns

ProShares Ultra Nasdaq Biotechnology holdings by asset type
Asset type% of fund
Stocks63.04%
Derivatives16.01%
Other6.80%
Repurchase agreements3.14%
Cash and short-term investments0.81%
ProShares Ultra Nasdaq Biotechnology holdings by country, largest 10
Country% of fund
United States79.81%
United Kingdom1.72%
Netherlands1.57%
Ireland1.19%
Bermuda1.08%
France0.95%
Denmark0.78%
Switzerland0.75%
Canada0.59%
Germany0.55%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to May 31, 2026, ProShares Ultra Nasdaq Biotechnology's total return was −3.99%, as reported to the SEC.

ProShares Ultra Nasdaq Biotechnology monthly total returns
MonthTotal return
May 31, 2026+3.79%
Apr 30, 2026+0.06%
Mar 31, 2026−7.55%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
ProShares Ultra Nasdaq Biotechnology
Ticker
BIB
Exchange
NASDAQ
Fund type
ETF
Trust
PROSHARES TRUST
SEC series ID
S000018718
SEC CIK
0001174610
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by PROSHARES TRUST, the trust behind ProShares Ultra Nasdaq Biotechnology, and cover all of its funds.

Frequently asked questions

What is BIB's price?

ProShares Ultra Nasdaq Biotechnology (BIB) closed at $361.27 on Oct 9, 2026, up 1.02% from the previous close of $357.62.

What does BIB hold?

ProShares Ultra Nasdaq Biotechnology held 267 investments worth $73.65M as of May 31, 2026. Its largest holding was N/A, at 7.35% of the fund. Its five largest holdings were N/A, ProShares GENIUS Money Market ETF, Gilead Sciences, Inc., Vertex Pharmaceuticals, Inc., Amgen, Inc..

How has BIB performed?

Over the 3 months to May 31, 2026, ProShares Ultra Nasdaq Biotechnology's total return was −3.99%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of May 31, 2026 (filed Jul 28, 2026). Prices are generated sample data for development. Data sources and disclosures